Regulation of ILC2s by Ang II is T cell independent.
(A) Ratio of peripheral blood immune cells from CD45.1 (AT1a+/+) and CD45.2 (AT1a−/−) mice was determined by flow cytometry after bone marrow reconstruction for 5 wk in recipient mice. (B) Percentages of donor lung CD4-derived type 2 cytokines in recipient mice. (C and D) Abundance of spleen CD19+ B, CD3+ T (C), and Gr1+ cells (D) from CD45.1 (AT1a+/+) and CD45.2 (AT1a−/−) mice upon Ang II or PBS administration is shown. (E–J) PBS or Ang II was i.n. administered daily for 5 consecutive days in Rag1−/− mice. (E) Flow cytometry of CD45+SiglecF+CD11c− eosinophils in BALF. (F) Concentration of IL-5 and IL-13 in BALF. (G) The absolute number of lung ILC2s, (H) the proliferation of lung ILC2s, and (I) cytokine production of lung ILC2s upon Ang II treatment. (J) Lung sections of control and Ang II–treated mice were stained with H&E. Data are two repeated independent experiments. (A–D)
n = 5/group. (E–J)
n = 4 or 5 /group. Scale bar, 100 μm. Graphical data show mean ± SEM by two-way ANOVA (B–D and F) and unpaired t test (E and G–I). *, P < 0.05; **, P < 0.01; ***, P < 0.001. Eos, eosinophil, Sp, spleen.